These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30625462)

  • 21. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
    Emerson CR; Marzella N
    Clin Ther; 2010 Aug; 32(9):1578-96. PubMed ID: 20974316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.
    Howden CW; Larsen LM; Perez MC; Palmer R; Atkinson SN
    Aliment Pharmacol Ther; 2009 Nov; 30(9):895-907. PubMed ID: 19681809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective Single Arm Study on the Effect of Ilaprazole in Patients with Heartburn but No Reflux Esophagitis.
    Song IJ; Kim HK; Lee NK; Lee SK
    Yonsei Med J; 2018 Oct; 59(8):951-959. PubMed ID: 30187702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of treatment pattern and symptom control in patients with gastroesophageal reflux disease: multihospital questionnaire survey on the current situation in Korea.
    Seo SI; Bang CS; Kang HS; Choi MH; Shin WG; Jang HJ; Kim JB; Baik KH; Kae SH; Kim HY
    Dis Esophagus; 2017 Oct; 30(10):1-8. PubMed ID: 28859382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor.
    Reimer C; Lødrup AB; Smith G; Wilkinson J; Bytzer P
    Aliment Pharmacol Ther; 2016 Apr; 43(8):899-909. PubMed ID: 26909885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
    Peura DA; Metz DC; Dabholkar AH; Paris MM; Yu P; Atkinson SN
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1010-21. PubMed ID: 19735233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors.
    Vakil NB; Huff FJ; Cundy KC
    Aliment Pharmacol Ther; 2013 Jul; 38(2):107-17. PubMed ID: 23721547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association.
    Aanen MC; Weusten BL; Numans ME; de Wit NJ; Samsom M; Smout AJ
    J Clin Gastroenterol; 2008; 42(5):441-7. PubMed ID: 18344896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 4 Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole.
    Wu JCY; Sheu BS; Wu MS; Lee YC; Choi MG
    J Neurogastroenterol Motil; 2020 Jan; 26(1):85-95. PubMed ID: 31597230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of 2-Week Data from Two Randomized, Controlled Trials Conducted in Subjects with Frequent Heartburn Treated with Esomeprazole 20 mg.
    Katz PO; Le Moigne A; Pollack C
    Clin Ther; 2017 May; 39(5):960-970. PubMed ID: 28431766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial.
    Ostovaneh MR; Saeidi B; Hajifathalian K; Farrokhi-Khajeh-Pasha Y; Fotouhi A; Mirbagheri SS; Emami H; Barzin G; Mirbagheri SA
    Neurogastroenterol Motil; 2014 May; 26(5):670-8. PubMed ID: 24533896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of symptoms and use of medication for gastroesophageal reflux in an Australian community.
    Watson DI; Lally CJ
    World J Surg; 2009 Jan; 33(1):88-94. PubMed ID: 18949510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.
    Ranaldo N; Losurdo G; Iannone A; Principi M; Barone M; De Carne M; Ierardi E; Di Leo A
    Cell Death Dis; 2017 Sep; 8(9):e3040. PubMed ID: 28880273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn.
    Dickman R; Schiff E; Holland A; Wright C; Sarela SR; Han B; Fass R
    Aliment Pharmacol Ther; 2007 Nov; 26(10):1333-44. PubMed ID: 17875198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained efficacy following resolution of frequent heartburn with an over-the-counter regimen of esomeprazole 20 mg or placebo for 14 days: two randomized trials.
    Peura DA; Le Moigne A; Wassel H; Pollack C
    BMC Gastroenterol; 2018 May; 18(1):69. PubMed ID: 29788903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data.
    Metz DC; Pilmer BL; Han C; Perez MC
    Am J Gastroenterol; 2011 Nov; 106(11):1953-60. PubMed ID: 21844923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study.
    Fass R; Delemos B; Nazareno L; Kao R; Xiang J; Lu Y
    Aliment Pharmacol Ther; 2010 May; 31(9):950-60. PubMed ID: 20132154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study.
    Vakil NB; Huff FJ; Bian A; Jones DS; Stamler D
    Am J Gastroenterol; 2011 Aug; 106(8):1427-38. PubMed ID: 21519360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease.
    Bayerdörffer E; Bigard MA; Weiss W; Mearin F; Rodrigo L; Dominguez Muñoz JE; Grundling H; Persson T; Svedberg LE; Keeling N; Eklund S
    BMC Gastroenterol; 2016 Apr; 16():48. PubMed ID: 27080034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.